Tag: Hawk Pharma Consulting
-
Optimisation of a Portfolio of Established Brands
by
Challenge: The problem with portfolios is that they are looked at as one and this does not reflect the reality. This portfolio was 15 medicines, the majority of which were in one therapy area. As a whole the portfolio was losing volumes year on year, losing revenue and losing margin to an even greater degree…
-
Category H introduction …. the end of branded generics in the UK?
by
Category H introduction has been announced although detail is lacking. It will undoubtedly affect branded generics and this article gives an outline as to how and why.
-
Repurposed molecule > Go-to-market & launch strategy > Operational structure options
by
Challenge: This Germany headquartered developer wanted to enter the UK market with a repurposed molecule (new form, new indication). They needed confirmation of the likely pricing window and volume forecast. They wanted advice on go-to-market and launch strategy and also the operational structure options to succeed in this less familiar, non-EU market.
-
Re-positioning an established “Alternative Brand” (branded-generic)
by
Challenge: In the UK, NHS advice is to prescribe some products (including drug / device combinations) by brand name when generics exist, so that patient continuity is ensured. With the launch of a new competitor branded-generic, this company’s alternative brand’s positioning was no longer compelling or even valid. We supported the UK affiliate to reposition…
-
Insight: the bedrock of any good plan … but KISS!
by
Insight is the bedrock of any good plan or business decision. Make sure you KISS (Keep It Simple Stupid) and focus on the data that matters, displaying it simply and graphically.
-
Established molecules – more than “just” generics?
by
A frequent response to hearing the words “established molecules” is “so you mean generics, right?” Well yes, and no! There is more to it than “just generics” and in fact this is an exciting and profitable area of pharma and one we love to work on here at Hawk Pharma Consulting.
-
Business Development (BD) – Target Product Profile (TPP) realignment to optimise success
by
Challenge: The challenges in the BD process include finding the finding the assets that you want, convincing the potential partner that you are right for their asset and making an appropriate offer that is accepted by both the partner’s, and your company’s, Board. To streamline efforts and optimise in-license success it was imperative for this…
-
OMD: Fractional, interim support from Hawk Pharma Consulting
by
We are delighted to add OMD, Our Marketing Department, to the offering from Hawk Pharma Consulting. Our fractional, interim marketing resource offering will help you turn plans into execution of materials, programs and tactics. For more detail: Our Marketing Department – Hawk Pharma Consulting
-
Environmental Focus & Sustainability – Building a compelling & compliant strategy & communication
by
Challenge: All companies feel compelled to talk about environmental focus and there is a danger that this can seem like “green-washing”. The NHS has a goal of becoming carbon net zero by 2040 and it has a focus on respiratory inhalers and gaseous anaesthetics as major contributor to the issue. We needed to develop a…
